Bausch Health Companies (BHC) Stock
Healthcare company with eye care and skin brands. Here's the price, business snapshot, and what's worth knowing about Bausch Health Companies in June 2026.
Bausch Health Companies Inc (BHC) is a diversified healthcare company known for prescription and consumer products in eye care, dermatology, gastroenterology and branded generics. Operating across North America, Europe and emerging markets, the company’s performance depends on product sales, pipeline development and how it manages pricing and patent expiries. Investors should be aware that BHC has a relatively small market capitalisation (~$2.3bn) and has historically carried significant leverage alongside episodic litigation and regulatory scrutiny — factors that can increase volatility and affect cash flow. Key watch points include product launches, integration of acquisitions, margin trends and debt reduction progress. This summary is educational only and not personalised advice; values can rise or fall and past performance is not a guide to future returns. Consider your risk tolerance and consult a financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Bausch Health's stock, with a target price indicating potential value increase.
Financial Health
Bausch Health is performing well with strong revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring BHC
J&J Talc Crisis Impact Explained | Health Stocks
A jury verdict found Johnson & Johnson liable in a talc cancer case, one of over 63,000 similar lawsuits the company faces. This ongoing legal crisis may drive consumers toward competitors, creating an investment opportunity in other personal care and consumer health companies.
Published: 15 February 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: 29 August 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: 5 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Revenue & Brands
Established prescription and consumer brands drive sales, while new launches and patent expiries shape growth — though revenues can fluctuate with market and competitive pressures.
Balance Sheet Focus
Leverage and debt reduction are important for valuation; successful deleveraging could improve prospects, but indebtedness and legal costs remain material risks.
Global Footprint
A presence across developed and emerging markets offers diversification and growth potential, yet it also brings currency, regulatory and pricing challenges.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
